AI Engines For more Details: Perplexity Kagi Labs You
Suppression of Cortisol Production: Metyrapone works by inhibiting an enzyme called 11-beta-hydroxylase, which is involved in the synthesis of cortisol, a hormone produced by the adrenal glands. By blocking this enzyme, metyrapone reduces the production of cortisol.
Diagnostic Testing for Adrenal Insufficiency: Metyrapone is commonly used in diagnostic testing to assess the function of the adrenal glands, particularly in cases of suspected adrenal insufficiency (also known as Addison's disease). In the metyrapone test, a single dose of metyrapone is administered to the patient, which temporarily suppresses cortisol production. Subsequent measurements of cortisol levels in the blood or urine help evaluate the integrity of the hypothalamic-pituitary-adrenal (HPA) axis, which regulates cortisol secretion.
Assessment of ACTH Responsiveness: In addition to diagnosing adrenal insufficiency, the metyrapone test can also help differentiate between primary adrenal insufficiency (due to dysfunction of the adrenal glands themselves) and secondary adrenal insufficiency (due to dysfunction of the pituitary gland or hypothalamus). In cases of secondary adrenal insufficiency, administration of metyrapone may lead to decreased cortisol production but increased secretion of adrenocorticotropic hormone (ACTH), which stimulates the adrenal glands.
Monitoring of Cushing's Syndrome: Metyrapone may also be used in the management of Cushing's syndrome, a condition characterized by excessive production of cortisol. By inhibiting cortisol synthesis, metyrapone can help reduce cortisol levels and alleviate symptoms associated with Cushing's syndrome, such as weight gain, hypertension, diabetes, and mood changes. However, other treatments are typically used for long-term management of Cushing's syndrome.
Side Effects: Metyrapone is generally well-tolerated when used for diagnostic testing under medical supervision. Common side effects may include gastrointestinal symptoms (such as nausea, vomiting, or abdominal discomfort), dizziness, headache, and fatigue. These side effects are usually mild and transient. However, the use of metyrapone may be associated with adrenal crisis in individuals with underlying adrenal insufficiency if not managed properly.
Contraindications: Metyrapone should be used with caution or avoided in individuals with liver dysfunction, as it is metabolized by the liver. It should also be used with caution in pregnant or breastfeeding women, as its safety in these populations has not been established. Additionally, metyrapone may interact with other medications, particularly those that affect liver enzyme activity or cortisol metabolism.
Rank | Probiotic | Impact |
---|---|---|
genus | Bifidobacterium | Reduces |
species | Anaerobutyricum hallii | Reduces |
species | Bacteroides uniformis | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium breve | Reduces |
species | Bifidobacterium longum | Reduces |
species | Christensenella minuta | Reduces |
species | Escherichia coli | Reduces |
species | Faecalibacterium prausnitzii | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
π Direct Citations | πͺπΆ Indirect Citations | Taxonomy | Rank | Effect |
---|---|---|---|---|
0 | 1 | Lachnospira | genus | Decreases |
0 | 1 | Clostridioides | genus | Decreases |
0 | 1 | Roseburia | genus | Decreases |
0 | 1 | Veillonella | genus | Decreases |
0 | 1 | Bifidobacterium | genus | Decreases |
0 | 1 | Eggerthella | genus | Decreases |
0 | 1 | Odoribacter | genus | Decreases |
0 | 1 | Coprococcus | genus | Decreases |
0 | 1 | Collinsella | genus | Decreases |
0 | 1 | Blautia | genus | Decreases |
0 | 1 | Bacteroides | genus | Decreases |
0 | 1 | Phocaeicola | genus | Decreases |
0 | 1 | Escherichia | genus | Decreases |
0 | 1 | Agathobacter | genus | Decreases |
0 | 1 | Ruminococcus | genus | Decreases |
0 | 1 | Segatella | genus | Decreases |
0 | 1 | Bilophila | genus | Decreases |
0 | 1 | Thomasclavelia | genus | Decreases |
0 | 1 | Escherichia coli O1:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O139:H1 | no rank | Decreases |
0 | 1 | Escherichia coli O141:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O145:H34 | no rank | Decreases |
0 | 1 | Escherichia coli O15:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O155:H21 | no rank | Decreases |
0 | 1 | Escherichia coli O158:H23 | no rank | Decreases |
0 | 1 | Escherichia coli O16:H48 | no rank | Decreases |
0 | 1 | Escherichia coli O170:H18 | no rank | Decreases |
0 | 1 | Escherichia coli O18ac:H14 | no rank | Decreases |
0 | 1 | Escherichia coli O19:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H5 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O20:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O25:H16 | no rank | Decreases |
0 | 1 | Escherichia coli O55:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O68:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O7:H15 | no rank | Decreases |
0 | 1 | Escherichia coli O78:H51 | no rank | Decreases |
0 | 1 | Escherichia coli O80:H26 | no rank | Decreases |
0 | 1 | Escherichia coli O84:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O85:H1 | no rank | Decreases |
0 | 1 | Escherichia coli O103 | serogroup | Decreases |
0 | 1 | Escherichia coli O111 | serogroup | Decreases |
0 | 1 | Escherichia coli O119 | serogroup | Decreases |
0 | 1 | Escherichia coli O121 | serogroup | Decreases |
0 | 1 | Escherichia coli O145 | serogroup | Decreases |
0 | 1 | Escherichia coli O155 | serogroup | Decreases |
0 | 1 | Escherichia coli O157 | serogroup | Decreases |
0 | 1 | Escherichia coli O177 | serogroup | Decreases |
0 | 1 | Escherichia coli O26 | serogroup | Decreases |
0 | 1 | Escherichia coli O3 | serogroup | Decreases |
0 | 1 | Escherichia coli O43 | serogroup | Decreases |
0 | 1 | Escherichia coli O5 | serogroup | Decreases |
0 | 1 | Escherichia coli O78 | serogroup | Decreases |
0 | 1 | Escherichia coli O86 | serogroup | Decreases |
0 | 1 | Escherichia coli O91 | serogroup | Decreases |
0 | 1 | Escherichia coli H20 | serotype | Decreases |
0 | 1 | Escherichia coli O1:H42 | serotype | Decreases |
0 | 1 | Escherichia coli O1:HNT | serotype | Decreases |
0 | 1 | Escherichia coli O10:H32 | serotype | Decreases |
0 | 1 | Escherichia coli O10:K5(L):H4 | serotype | Decreases |
0 | 1 | Escherichia coli O100:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H- | serotype | Decreases |
0 | 1 | Escherichia coli O111:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O111:NM | serotype | Decreases |
0 | 1 | Escherichia coli O112ab:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O112ac:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O113:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O114:H49 | serotype | Decreases |
0 | 1 | Escherichia coli O118:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O123:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O125ac:K+:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O126:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H27 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O128:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O128ac:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O139:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O145:NM | serotype | Decreases |
0 | 1 | Escherichia coli O146:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O15:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O150:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O152:H23 | serotype | Decreases |
0 | 1 | Escherichia coli O153:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O156:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H- | serotype | Decreases |
0 | 1 | Escherichia coli O157:H43 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O157:NM | serotype | Decreases |
0 | 1 | Escherichia coli O16:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O165:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O167:H26 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O176:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O177:NM | serotype | Decreases |
0 | 1 | Escherichia coli O2:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O2:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O25:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O25:NM | serotype | Decreases |
0 | 1 | Escherichia coli O26:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O26:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O28ac:NM | serotype | Decreases |
0 | 1 | Escherichia coli O29:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O32:H37 | serotype | Decreases |
0 | 1 | Escherichia coli O39:NM | serotype | Decreases |
0 | 1 | Escherichia coli O44:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O45:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16:CFA/II | serotype | Decreases |
0 | 1 | Escherichia coli O6:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O69:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O7:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O7:K1 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O79:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O8:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O81:NM | serotype | Decreases |
0 | 1 | Escherichia coli O83:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O86:H34 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H9 | serotype | Decreases |
0 | 1 | Escherichia coli O9:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O91:H14 | serotype | Decreases |
0 | 1 | Escherichia coli O91:NM | serotype | Decreases |
0 | 1 | Escherichia coli O99:H6 | serotype | Decreases |
0 | 1 | Escherichia coli ONT:H33 | serotype | Decreases |
1 | 0 | Lachnospira eligens | species | Decreases |
1 | 0 | Bifidobacterium longum | species | Decreases |
1 | 0 | Clostridioides difficile | species | Decreases |
1 | 0 | Roseburia hominis | species | Decreases |
1 | 0 | Veillonella parvula | species | Decreases |
1 | 0 | Eggerthella lenta | species | Decreases |
1 | 0 | Odoribacter splanchnicus | species | Decreases |
1 | 0 | Bacteroides ovatus | species | Decreases |
1 | 0 | Coprococcus comes | species | Decreases |
1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
1 | 0 | Bifidobacterium adolescentis | species | Decreases |
1 | 0 | Collinsella aerofaciens | species | Decreases |
1 | 0 | Blautia obeum | species | Decreases |
1 | 0 | Bacteroides xylanisolvens | species | Decreases |
0 | 1 | Bifidobacterium breve | species | Decreases |
0 | 1 | Veillonella rodentium | species | Decreases |
0 | 1 | Veillonella dispar | species | Decreases |
0 | 1 | Butyrivibrio crossotus | species | Decreases |
0 | 1 | Eggerthella guodeyinii | species | Decreases |
0 | 1 | Coprococcus catus | species | Decreases |
0 | 1 | Veillonella sp. S12025-13 | species | Decreases |
0 | 1 | Subdoligranulum variabile | species | Decreases |
0 | 1 | Wansuia hejianensis | species | Decreases |
0 | 1 | Veillonella nakazawae | species | Decreases |
0 | 1 | Ligilactobacillus ruminis | species | Decreases |
0 | 1 | Clostridium sp. M62/1 | species | Decreases |
0 | 1 | Anaerobutyricum hallii | species | Decreases |
0 | 1 | Dorea longicatena | species | Decreases |
0 | 1 | Dorea formicigenerans | species | Decreases |
0 | 1 | Clostridium sp. SY8519 | species | Decreases |
0 | 1 | Eubacterium sp. MSJ-33 | species | Decreases |
0 | 1 | Faecalibacterium duncaniae | species | Decreases |
0 | 1 | Blautia sp. SC05B48 | species | Decreases |
1 | 0 | Bacteroides caccae | species | Decreases |
0 | 1 | Roseburia rectibacter | species | Decreases |
0 | 1 | Lacrimispora saccharolytica | species | Decreases |
0 | 1 | Christensenella minuta | species | Decreases |
0 | 1 | Eubacterium ventriosum | species | Decreases |
0 | 1 | [Ruminococcus] lactaris | species | Decreases |
0 | 1 | Qiania dongpingensis | species | Decreases |
0 | 1 | Wujia chipingensis | species | Decreases |
0 | 1 | Veillonella rogosae | species | Decreases |
0 | 1 | Coprococcus eutactus | species | Decreases |
0 | 1 | Pseudobutyrivibrio xylanivorans | species | Decreases |
0 | 1 | Simiaoa sunii | species | Decreases |
0 | 1 | Komagataeibacter oboediens | species | Decreases |
0 | 1 | Maliibacterium massiliense | species | Decreases |
0 | 1 | Massilistercora timonensis | species | Decreases |
0 | 1 | Novisyntrophococcus fermenticellae | species | Decreases |
0 | 1 | Blautia liquoris | species | Decreases |
0 | 1 | Roseburia intestinalis | species | Decreases |
0 | 1 | [Clostridium] hylemonae | species | Decreases |
0 | 1 | Catenibacterium mitsuokai | species | Decreases |
0 | 1 | Marvinbryantia formatexigens | species | Decreases |
0 | 1 | Ruminococcus champanellensis | species | Decreases |
0 | 1 | Faecalitalea cylindroides | species | Decreases |
0 | 1 | Faecalibacterium prausnitzii | species | Decreases |
0 | 1 | Vescimonas fastidiosa | species | Decreases |
0 | 1 | Faecalibacterium sp. I2-3-92 | species | Decreases |
0 | 1 | Coprococcus sp. ART55/1 | species | Decreases |
0 | 1 | Faecalibacterium sp. I4-1-79 | species | Decreases |
0 | 1 | Intestinibaculum porci | species | Decreases |
0 | 1 | Faecalibacterium sp. I3-3-33 | species | Decreases |
0 | 1 | Lachnoclostridium phocaeense | species | Decreases |
0 | 1 | Bifidobacterium angulatum | species | Decreases |
0 | 1 | Faecalibacterium sp. IP-3-29 | species | Decreases |
0 | 1 | Clostridium cadaveris | species | Decreases |
0 | 1 | Catenibacterium sp. co_0103 | species | Decreases |
1 | 0 | Phocaeicola vulgatus | species | Decreases |
0 | 1 | Ruminococcus bicirculans (ex Wegman et al. 2014) | species | Decreases |
0 | 1 | Faecalibacterium sp. I3-3-89 | species | Decreases |
1 | 0 | Escherichia coli | species | Decreases |
1 | 0 | Agathobacter rectalis | species | Decreases |
1 | 0 | Ruminococcus bromii | species | Decreases |
1 | 0 | Segatella copri | species | Decreases |
1 | 0 | Bilophila wadsworthia | species | Decreases |
1 | 0 | Thomasclavelia ramosa | species | Decreases |
1 | 0 | Bacteroides uniformis | species | Decreases |
0 | 1 | Bifidobacterium longum subsp. infantis | subspecies | Decreases |
0 | 1 | Bifidobacterium longum subsp. longum | subspecies | Decreases |
0 | 1 | Bifidobacterium longum subsp. suillum | subspecies | Decreases |
0 | 1 | Bifidobacterium longum subsp. suis | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
Acne | 0.2 | -0.2 | |
ADHD | 1.8 | 0.6 | 2 |
Age-Related Macular Degeneration and Glaucoma | 0.4 | 0.4 | |
Allergic Rhinitis (Hay Fever) | 0.5 | 1.2 | -1.4 |
Allergies | 2.6 | 0.8 | 2.25 |
Allergy to milk products | 0.5 | 0.5 | 0 |
Alopecia (Hair Loss) | 0.2 | 0.1 | 1 |
Alzheimer's disease | 1.3 | 2.4 | -0.85 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.2 | 0.1 | 11 |
Ankylosing spondylitis | 1.2 | 0.4 | 2 |
Anorexia Nervosa | 0.3 | 1.1 | -2.67 |
Antiphospholipid syndrome (APS) | 0.4 | 0 | 0 |
Asthma | 2.4 | 1.1 | 1.18 |
Atherosclerosis | 0.6 | 0.7 | -0.17 |
Atrial fibrillation | 1.2 | 0.5 | 1.4 |
Autism | 2.6 | 3.4 | -0.31 |
Autoimmune Disease | 0.2 | 0.4 | -1 |
Barrett esophagus cancer | 0.2 | 0.2 | |
benign prostatic hyperplasia | 0 | 0.1 | 0 |
Biofilm | 0.3 | 0.3 | |
Bipolar Disorder | 0.5 | 0.8 | -0.6 |
Brain Trauma | 0.3 | 0.7 | -1.33 |
Breast Cancer | 0.1 | 0.1 | |
Cancer (General) | 0.4 | 1.1 | -1.75 |
Carcinoma | 0.9 | 0.7 | 0.29 |
Celiac Disease | 1.1 | 1.7 | -0.55 |
Cerebral Palsy | 0.5 | 0.5 | 0 |
Chronic Fatigue Syndrome | 1.7 | 2.3 | -0.35 |
Chronic Kidney Disease | 1.4 | 1.2 | 0.17 |
Chronic Lyme | 0.5 | 0.3 | 0.67 |
Chronic Obstructive Pulmonary Disease (COPD) | 0.4 | 0.9 | -1.25 |
Chronic Urticaria (Hives) | 0.3 | 0.2 | 0.5 |
Coagulation / Micro clot triggering bacteria | 0.1 | 0.4 | -3 |
Cognitive Function | 0.4 | 0.6 | -0.5 |
Colorectal Cancer | 1.1 | 0.9 | 0.22 |
Constipation | 0.6 | 0.4 | 0.5 |
Coronary artery disease | 0.4 | 1.2 | -2 |
COVID-19 | 3.5 | 4.4 | -0.26 |
Crohn's Disease | 1.8 | 2.2 | -0.22 |
Cushing's Syndrome (hypercortisolism) | 0.2 | -0.2 | |
cystic fibrosis | 0.1 | 0.9 | -8 |
d-lactic acidosis (one form of brain fog) | 0.1 | 0.1 | |
deep vein thrombosis | 0.3 | 0.4 | -0.33 |
Denture Wearers Oral Shifts | 0.4 | 0.4 | |
Depression | 3.3 | 3.7 | -0.12 |
Dermatomyositis | 0.2 | -0.2 | |
Eczema | 0.3 | 0.4 | -0.33 |
Endometriosis | 0.8 | 1.2 | -0.5 |
Eosinophilic Esophagitis | 0.2 | -0.2 | |
Epilepsy | 0.9 | 0.4 | 1.25 |
erectile dysfunction | 0.1 | 0.2 | -1 |
Fibromyalgia | 0.8 | 0.7 | 0.14 |
Functional constipation / chronic idiopathic constipation | 2.1 | 1 | 1.1 |
gallstone disease (gsd) | 0.5 | 0.4 | 0.25 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.4 | 0.8 | -1 |
Generalized anxiety disorder | 0.7 | 1 | -0.43 |
Gout | 0.4 | 0.1 | 3 |
Graves' disease | 0.6 | 1.1 | -0.83 |
Gulf War Syndrome | 0.2 | 0.4 | -1 |
Halitosis | 0.3 | 0.3 | |
Hashimoto's thyroiditis | 1 | 0.7 | 0.43 |
Heart Failure | 1.5 | 0.9 | 0.67 |
Hidradenitis Suppurativa | 0.4 | 0.2 | 1 |
High Histamine/low DAO | 0.3 | 0.2 | 0.5 |
hypercholesterolemia (High Cholesterol) | 0.3 | 0.3 | |
hyperglycemia | 0.5 | 0.5 | 0 |
Hyperlipidemia (High Blood Fats) | 0.3 | 0.1 | 2 |
hypersomnia | 0.2 | -0.2 | |
hypertension (High Blood Pressure | 0.9 | 3.2 | -2.56 |
Hypothyroidism | 0.6 | -0.6 | |
Hypoxia | 0.3 | 0.3 | |
IgA nephropathy (IgAN) | 0.3 | 2.3 | -6.67 |
Inflammatory Bowel Disease | 3 | 3.5 | -0.17 |
Insomnia | 0.7 | 1 | -0.43 |
Intelligence | 0.5 | 0.2 | 1.5 |
Intracranial aneurysms | 0.2 | 0.2 | 0 |
Irritable Bowel Syndrome | 2 | 1.8 | 0.11 |
ischemic stroke | 1.3 | 0.5 | 1.6 |
Liver Cirrhosis | 2.4 | 1 | 1.4 |
Long COVID | 2.4 | 3.9 | -0.63 |
Low bone mineral density | 0.8 | -0.8 | |
Lung Cancer | 0.2 | 0.4 | -1 |
Lymphoma | 0 | 0 | |
Mast Cell Issues / mastitis | 0 | 0.4 | 0 |
ME/CFS with IBS | 1.4 | -1.4 | |
ME/CFS without IBS | 0.7 | 0.6 | 0.17 |
Menopause | 1.4 | 0.2 | 6 |
Metabolic Syndrome | 1.9 | 3 | -0.58 |
Mood Disorders | 3.7 | 3 | 0.23 |
multiple chemical sensitivity [MCS] | 0.2 | 0.2 | 0 |
Multiple Sclerosis | 1.9 | 1.7 | 0.12 |
Multiple system atrophy (MSA) | 0.5 | 0.3 | 0.67 |
myasthenia gravis | 0 | 0.2 | 0 |
neuropathic pain | 0.2 | 1.7 | -7.5 |
Neuropathy (all types) | 0.3 | 0.7 | -1.33 |
neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.7 | 2.5 | -0.47 |
NonCeliac Gluten Sensitivity | 0.7 | 0.3 | 1.33 |
Obesity | 3.6 | 2.4 | 0.5 |
obsessive-compulsive disorder | 2.2 | 0.8 | 1.75 |
Osteoarthritis | 0.4 | 0.5 | -0.25 |
Osteoporosis | 0.8 | 0.4 | 1 |
pancreatic cancer | 0.2 | 0.2 | |
Parkinson's Disease | 2.6 | 2 | 0.3 |
Polycystic ovary syndrome | 1.3 | 0.9 | 0.44 |
Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
Premenstrual dysphoric disorder | 0.4 | 0.4 | |
primary biliary cholangitis | 0.2 | 0.1 | 1 |
Primary sclerosing cholangitis | 0.8 | 0.7 | 0.14 |
Psoriasis | 1 | 0.6 | 0.67 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.5 | 1.4 | 0.79 |
Rosacea | 0.2 | 0.4 | -1 |
Schizophrenia | 2.8 | 1.3 | 1.15 |
scoliosis | 0.3 | 0.6 | -1 |
sensorineural hearing loss | 0.1 | 0.1 | |
Sjögren syndrome | 1.1 | 0.8 | 0.38 |
Sleep Apnea | 0.5 | 0.8 | -0.6 |
Slow gastric motility / Gastroparesis | 0.4 | 0.2 | 1 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.5 | 0.6 | -0.2 |
Stress / posttraumatic stress disorder | 0.6 | 1.3 | -1.17 |
Systemic Lupus Erythematosus | 0.9 | 1.2 | -0.33 |
Tic Disorder | 0.3 | 0.6 | -1 |
Tourette syndrome | 0.1 | -0.1 | |
Type 1 Diabetes | 1 | 2.2 | -1.2 |
Type 2 Diabetes | 2.2 | 2 | 0.1 |
Ulcerative colitis | 1.2 | 2.8 | -1.33 |
Unhealthy Ageing | 1.3 | 0.8 | 0.63 |
Vitiligo | 0.6 | 0.5 | 0.2 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]